Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
About Definium Therapeutics
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in
For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260219692160/en/
Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
IR@definiumtx.com
Media Contact:
media@definiumtx.com
Source: Definium Therapeutics, Inc.
